Filing Details

Accession Number:
0001104659-19-002543
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-01-18 20:58:12
Reporting Period:
2019-01-17
Accepted Time:
2019-01-18 20:58:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1650664 Editas Medicine Inc. EDIT Biological Products, (No Disgnostic Substances) (2836) 464097528
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1742806 Vickesh Myer C/O Editas Medicine, Inc.
11 Hurley Street
Cambridge MA 02141
Chief Technology Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-01-17 3,000 $0.65 3,000 No 4 M Direct
Common Stock Disposition 2019-01-17 3,000 $26.18 0 No 4 S Direct
Common Stock Acquisiton 2019-01-18 4,000 $11.21 4,000 No 4 M Direct
Common Stock Disposition 2019-01-18 4,000 $26.50 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2019-01-17 3,000 $0.00 3,000 $0.65
Common Stock Stock Option (right to buy) Disposition 2019-01-18 4,000 $0.00 4,000 $11.21
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
79,307 2025-04-29 No 4 M Direct
52,897 2025-10-29 No 4 M Direct
Footnotes
  1. The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.
  2. This transaction was executed in multiple trades at prices ranging from $26.03 to $26.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and the prices at which the transaction was effected.
  3. This option was granted on April 30, 2015 and is scheduled to vest over four years, with 25% of the shares having vested on April 21, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through April 21, 2019.
  4. This option was granted on October 30, 2015 and is scheduled to vest over four years, with 25% of the shares having vested on October 27, 2016 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 27, 2019.